An open-label, dose-escalation Phase 1/2 study is underway assessing Incyte's (NASDAQ:INCY) INCAGN1949 in patients with advanced/metastatic solid tumors. The first stage will evaluate safety and tolerability while the second stage will assess the recommended dose.
According to ClinicalTrials.gov, the estimated final data collection date for the primary endpoint is December 2018. The estimated study completion date is February 2019.
INCAGN1949 is a monoclonal antibody that binds to an immune checkpoint receptor called OX40, also known as CD134 or TNFRSF4. It is a co-stimulatory receptor found on activated T cells. Targeting OX40 stimulates the immune response to promote the killing of cancer cells and inhibits the activity of regulatory T cells that mediate immune suppression.